On May 12, 2025, the European Medicines Agency (EMA) published on its website information about a shortage of NovoSeven (eptacog alfa) in several EU countries.

The supply shortage or limited availability affects some of the Member States where the medicine is marketed, including Belgium, Denmark, France, Germany, Luxembourg and Sweden; in some Member States, English-labelled packs for certain doses will be available until the end of 2025.

 Recommendations for patients and carriers:

• Due to manufacturing issues, there are supply shortages or limited availability of NovoSeven in some EU countries.
• If NovoSeven is not available, your doctor may prescribe a different medicine.
• When you receive NovoSeven, it may be accompanied by information in English (on the box and package leaflet). If you need help understanding the information or have any other questions, speak to your doctor or pharmacist.
• For additional information about the supply of NovoSeven, consult your country’s shortage register or contact your national competent authority.

The EHC will keep monitoring closely the situation with availability of NovoSeven in its member countries.